Five Prime Therapeutics

About:

FivePrime is a clinical-stage biotechnology company that develops treatments for cancers.

Website: http://www.fiveprime.com

Twitter/X: FivePrime_FPRX

Top Investors: TPG, Wellcome Trust, Kleiner Perkins, Versant Ventures, HealthCap

Description:

FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures.

Total Funding Amount:

$345M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2001-01-01

Contact Email:

business.development(AT)fiveprime.com

Founders:

Lewis Williams

Number of Employees:

101-250

Last Funding Date:

2018-01-01

IPO Status:

Delisted

© 2025 bioDAO.ai